Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolism of (R)-(+)-Pulegone and (R)-(+)-Menthofuran by Human Liver Cytochrome P-450s: Evidence for Formation of a Furan Epoxide

Siamak C. Khojasteh-Bakht, Weiqiao Chen, Luke L. Koenigs, Raimund M. Peter and Sidney D. Nelson
Drug Metabolism and Disposition May 1999, 27 (5) 574-580;
Siamak C. Khojasteh-Bakht
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weiqiao Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luke L. Koenigs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raimund M. Peter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sidney D. Nelson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

(R)-(+)-Pulegone, a monoterpene constituent of pennyroyal oil, is a hepatotoxin that has been used in folklore medicine as an abortifacient despite its potential lethal effects. Pulegone is metabolized by human liver cytochrome P-450s to menthofuran, a proximate hepatotoxic metabolite of pulegone. Expressed human liver cytochrome (CYP) P-450s (1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4) were tested for their ability to catalyze the oxidations of pulegone and menthofuran. Expressed CYP2E1, CYP1A2, and CYP2C19 oxidized pulegone to menthofuran, with respectiveKm and Vmaxvalues of 29 μM and 8.4 nmol/min/nmol P-450 for CYP2E1, 94 μM and 2.4 nmol/min/nmol P-450 for CYP1A2, and 31 μM and 1.5 nmol/min/nmol P-450 for CYP2C19. The human liver P-450s involved in the metabolism of menthofuran are the same as pulegone except for the addition of CYP2A6. These P-450s were found to oxidize menthofuran to a newly identified metabolite, 2-hydroxymenthofuran, which is an intermediate in the formation of the known metabolites mintlactone and isomintlactone. Based on studies with 18O2 and H218O, 2-hydroxymenthofuran arises predominantly from a dihydrodiol formed from a furan epoxide. CYP2E1, CYP1A2, and CYP2C19 oxidized menthofuran with respectiveKm andVmax values of 33 μM and 0.43 nmol/min/nmol P-450 for CYP2E1, 57 μM and 0.29 nmol/min/nmol P-450 for CYP1A2, and 62 μM and 0.26 nmol/min/nmol P-450 for CYP2C19.

Footnotes

  • Send reprint requests to: Sidney D. Nelson, Ph.D., Medicinal Chemistry, University of Washington, Box 357610, Seattle, WA 98195-7610. E-mail: sidnels{at}u.washington.edu

  • This work was supported by National Institutes of Health Grants GM 25418 and GM 32165 (to S.D.N.).

  • Abbreviations used are::
    DDC
    diethyldithiocarbamate
    DLPC
    dilauryl-dl-α-phosphatidylcholine
    dimethoxymenthofuran
    α,α′-dimethoxydihydromenthofuran
    HL
    human liver microsomes
    2-hydroxymenthofuran
    (R)-2-hydroxymenthofuran
    isomintlactone
    (+)-isomintlactone
    menthofuran
    (R)-(+)-menthofuran
    mintlactone
    (−)-mintlactone
    P-450
    human liver cytochrome P-450
    pulegone
    (R)-(+)-pulegone
    r
    correlation coefficient
    TDC
    5,6,7,8-tetrahydro-4,7-dimethyl-7H-cinnoline
    • Received November 9, 1998.
    • Accepted January 29, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (5)
Drug Metabolism and Disposition
Vol. 27, Issue 5
1 May 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolism of (R)-(+)-Pulegone and (R)-(+)-Menthofuran by Human Liver Cytochrome P-450s: Evidence for Formation of a Furan Epoxide
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Metabolism of (R)-(+)-Pulegone and (R)-(+)-Menthofuran by Human Liver Cytochrome P-450s: Evidence for Formation of a Furan Epoxide

Siamak C. Khojasteh-Bakht, Weiqiao Chen, Luke L. Koenigs, Raimund M. Peter and Sidney D. Nelson
Drug Metabolism and Disposition May 1, 1999, 27 (5) 574-580;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Metabolism of (R)-(+)-Pulegone and (R)-(+)-Menthofuran by Human Liver Cytochrome P-450s: Evidence for Formation of a Furan Epoxide

Siamak C. Khojasteh-Bakht, Weiqiao Chen, Luke L. Koenigs, Raimund M. Peter and Sidney D. Nelson
Drug Metabolism and Disposition May 1, 1999, 27 (5) 574-580;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PK-PD studies of active ingredient in CH-I
  • IVIVE of aldehyde oxidase-mediated clearance
  • ALTBio Consortium developed for drug metabolism research.
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics